Literature DB >> 30585794

Cardiac Manifestations in Idiopathic Inflammatory Myopathies: An Overview.

Divya Jayakumar1, Rui Zhang, Amy Wasserman, Julia Ash.   

Abstract

Idiopathic inflammatory myopathies are a group of autoimmune diseases that are characterized by muscle inflammation resulting in elevated muscle enzyme release and distinctive biopsy findings. This group of conditions includes polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy. Although they have many similarities, the inflammatory myopathies differ in their clinical, pathological, and treatment realms. Extramuscular manifestations may involve many organs that include the skin, joints, heart, lungs, and gastrointestinal tract. Cardiovascular involvement is one of the leading causes of mortality in polymyositis and dermatomyositis. Surveillance and prevention of cardiovascular risk factors are therefore essential. In this article, we review the epidemiology, pathophysiology, clinical manifestations, diagnosis, and management of cardiovascular complications of idiopathic inflammatory myopathies with the main focus on polymyositis and dermatomyositis.

Entities:  

Mesh:

Year:  2019        PMID: 30585794     DOI: 10.1097/CRD.0000000000000241

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  10 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

2.  [Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement].

Authors:  L Luo; X Y Xing; Y S Xiao; K Y Chen; F Y Zhu; X W Zhang; Y H Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

3.  [Clinical and immunological characteristics of 88 cases of overlap myositis].

Authors:  Y S Xiao; F Y Zhu; L Luo; X Y Xing; Y H Li; X W Zhang; D H Shen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

4.  Quantitative assessment of left ventricular myocardial involvement in patients with connective tissue disease: a 3.0T contrast-enhanced cardiovascular magnetic resonance study.

Authors:  Jin Wang; Yue Gao; Zhi-Gang Yang; Ying-Kun Guo; Li Jiang; Rui Shi; Hua-Yan Xu; Shan Huang; Yuan Li
Journal:  Int J Cardiovasc Imaging       Date:  2022-03-13       Impact factor: 2.357

5.  Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry.

Authors:  Lixi Zhang; Huiyi Zhu; Pinting Yang; Xinwang Duan; Wei Wei; Zhenbiao Wu; Yongfei Fang; Qin Li; Shengyun Liu; Xiaofei Shi; Hongbin Li; Chanyuan Wu; Shuang Zhou; Xiaomei Leng; Jiuliang Zhao; Dong Xu; Qingjun Wu; Xinping Tian; Mengtao Li; Yan Zhao; Qian Wang; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2021-06-29       Impact factor: 2.980

Review 6.  Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature.

Authors:  Bruno Corrado; Gianluca Ciardi; Laura Lucignano
Journal:  Neurol Int       Date:  2020-11-24

7.  The correlation between cardiac and skeletal muscle pathology in animal models of idiopathic inflammatory myopathies.

Authors:  Francesco Prisco; Serenella Papparella; Orlando Paciello
Journal:  Acta Myol       Date:  2020-12-01

Review 8.  Arrhythmias and Conduction Disturbances in Autoimmune Rheumatic Disorders.

Authors:  Sotiris C Plastiras; Haralampos M Moutsopoulos
Journal:  Arrhythm Electrophysiol Rev       Date:  2021-04

Review 9.  Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.

Authors:  Buel D Rodgers; Christopher W Ward
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

10.  Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies.

Authors:  Li Qin; Yiwen Zhang; Xiaoqian Yang; Han Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-05-11       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.